ES2273441T5 - Combinaciones de inhibidores de enzima cyp2a y de nicotina y su utilizon terapeutica. - Google Patents

Combinaciones de inhibidores de enzima cyp2a y de nicotina y su utilizon terapeutica. Download PDF

Info

Publication number
ES2273441T5
ES2273441T5 ES98956735T ES98956735T ES2273441T5 ES 2273441 T5 ES2273441 T5 ES 2273441T5 ES 98956735 T ES98956735 T ES 98956735T ES 98956735 T ES98956735 T ES 98956735T ES 2273441 T5 ES2273441 T5 ES 2273441T5
Authority
ES
Spain
Prior art keywords
cyp2a6
nicotine
individual
smoking
tobacco
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98956735T
Other languages
English (en)
Spanish (es)
Other versions
ES2273441T3 (es
Inventor
Edward M. Sellers
Rachel F. Tyndale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nicogen Inc
Original Assignee
Nicogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27490603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2273441(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nicogen Inc filed Critical Nicogen Inc
Application granted granted Critical
Publication of ES2273441T3 publication Critical patent/ES2273441T3/es
Publication of ES2273441T5 publication Critical patent/ES2273441T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Enzymes And Modification Thereof (AREA)
ES98956735T 1997-12-01 1998-12-01 Combinaciones de inhibidores de enzima cyp2a y de nicotina y su utilizon terapeutica. Expired - Lifetime ES2273441T5 (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US6702197P 1997-12-01 1997-12-01
US6702097P 1997-12-01 1997-12-01
US67021P 1997-12-01
US67020P 1997-12-01
US8484798P 1998-05-08 1998-05-08
US84847P 1998-05-08
US10739298P 1998-11-06 1998-11-06
US107392P 1998-11-06

Publications (2)

Publication Number Publication Date
ES2273441T3 ES2273441T3 (es) 2007-05-01
ES2273441T5 true ES2273441T5 (es) 2010-06-28

Family

ID=27490603

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98956735T Expired - Lifetime ES2273441T5 (es) 1997-12-01 1998-12-01 Combinaciones de inhibidores de enzima cyp2a y de nicotina y su utilizon terapeutica.

Country Status (12)

Country Link
EP (1) EP1033979B2 (enExample)
JP (1) JP2001524516A (enExample)
CN (1) CN100362995C (enExample)
AT (1) ATE335484T1 (enExample)
AU (1) AU762671C (enExample)
BR (1) BR9815128A (enExample)
CA (1) CA2312851A1 (enExample)
DE (1) DE69835534T3 (enExample)
ES (1) ES2273441T5 (enExample)
NZ (1) NZ505439A (enExample)
PT (1) PT1033979E (enExample)
WO (1) WO1999027919A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9900490D0 (sv) * 1999-02-15 1999-02-15 A & Science Invest Ab Diagnostic agent and method
GB9927806D0 (en) * 1999-11-24 2000-01-26 Isis Innovation Genetic indicators of tobacco consumption
US6492115B1 (en) 2000-06-02 2002-12-10 Dna Sciences Laboratories, Inc. Genetic typing of the human cytochrome P450 2A6 gene and related materials and methods
US8688385B2 (en) * 2003-02-20 2014-04-01 Mayo Foundation For Medical Education And Research Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
CN1308462C (zh) * 2003-09-22 2007-04-04 周宏灏 个体化用药基因型诊断芯片及其制造方法和应用方法
KR100829122B1 (ko) * 2006-12-05 2008-05-13 한국과학기술연구원 당귀 추출물 또는 이로부터 분리한 쿠마린계 화합물을 유효성분으로 함유하는 폐암 예방용 조성물
EP2031072A1 (en) * 2007-08-27 2009-03-04 Andreas Ziegler Method for in-vitro diagnosing a predisposition to smoking and a pharmaceutical composition for treating tobacco abuse
JP5275060B2 (ja) * 2009-01-30 2013-08-28 学校法人近畿大学 Ｃｙｐ２ａ６阻害剤及びｃｙｐ２ａ６阻害活性物質のスクリーニング方法
CN104004852B (zh) * 2014-06-17 2015-12-02 陕西佰美基因股份有限公司 一种基于荧光定量pcr检测cyp2a6全基因缺失的方法
EP3157519B1 (en) 2014-06-19 2021-05-12 Immunolight, LLC Methods and systems for treating cell proliferation disorders with psoralen derivatives
EP3207924A1 (de) 2016-02-17 2017-08-23 Flaxan GmbH & Co. KG Pharmazeutische zubereitung zur hemmung humaner cyp-enzyme
CN116183779B (zh) * 2023-04-18 2025-01-24 云南省烟草农业科学研究院 基于一步净化和液相色谱-串联质谱的烟气中TSNAs测定方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2066998C1 (ru) * 1992-06-25 1996-09-27 Валерий Иванович Вольвич Способ получения средства для лечения вирусного гепатита а
WO1995034679A2 (en) * 1994-06-16 1995-12-21 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Defects in drug metabolism
DE19646977A1 (de) * 1995-09-29 1998-01-15 Schwabe Willmar Gmbh & Co Stabiler Extrakt aus Hypericum perforatum L., Verfahren zu seiner Herstellung und pharmazeutische Zubereitungen
EP0954304A2 (en) † 1996-07-17 1999-11-10 Nicogen Inc. Methods for regulating nicotine metabolism

Also Published As

Publication number Publication date
JP2001524516A (ja) 2001-12-04
AU1328699A (en) 1999-06-16
CN1299276A (zh) 2001-06-13
EP1033979B2 (en) 2010-02-24
CN100362995C (zh) 2008-01-23
PT1033979E (pt) 2006-12-29
EP1033979A2 (en) 2000-09-13
CA2312851A1 (en) 1999-06-10
EP1033979B9 (en) 2007-02-28
AU762671C (en) 2004-11-18
DE69835534D1 (de) 2006-09-21
BR9815128A (pt) 2000-10-10
ES2273441T3 (es) 2007-05-01
WO1999027919A2 (en) 1999-06-10
AU762671B2 (en) 2003-07-03
WO1999027919A3 (en) 1999-08-12
NZ505439A (en) 2005-02-25
EP1033979B1 (en) 2006-08-09
DE69835534T3 (de) 2010-09-23
ATE335484T1 (de) 2006-09-15
DE69835534T2 (de) 2007-08-09

Similar Documents

Publication Publication Date Title
US7371414B2 (en) Therapeutic and diagnostic methods dependent on CYP2A enzymes
Cupp et al. Cytochrome P450: new nomenclature and clinical implications
Lewis et al. Monoamine oxidase and tobacco dependence
Tutka et al. Pharmacokinetics and metabolism of nicotine
Alsharari et al. Effects of menthol on nicotine pharmacokinetic, pharmacology and dependence in mice
ES2273441T5 (es) Combinaciones de inhibidores de enzima cyp2a y de nicotina y su utilizon terapeutica.
US20210379017A1 (en) Methods and Compositions for Treating Psychotic Disorders
Chandy et al. Adverse impact of cannabis on human health
US20230277630A1 (en) Methods and compositions for treating amyotrophic lateral sclerosis
US20090285797A1 (en) Use of inhibitors of cyp2a6 for regulating nicotine metabolism
US20020016325A1 (en) New drug combinations
US20080319025A1 (en) Therapeutic and Diagnostic Methods Dependent on CYP2A Enzymes
AU742628B2 (en) Methods for regulating nicotine metabolism
US20020049230A1 (en) New treatments for nervous disorders
ZA200005301B (en) New drug combinations of a N.A.R.I., preferably reboxetine, and pindolol.
US20070248702A1 (en) Use of CB2 receptors agonists for the treatment of Huntington's disease
AU2003268826A1 (en) CYP2A enzymes and their use in therapeutic and diagnostic methods
Li et al. Influence of Sevoflurane Postconditioning on Hypoxic-Ischemic Brain Injury via Nrf2-Regulated Ferroptosis in Neonatal Rats
Casey Metabolism and excretion: eliminating drugs from the body
MXPA00005446A (en) Therapeutic and diagnostic methods dependent on cyp2a enzymes
CA2227403A1 (en) Oral nicotine composition and methods
Rosen et al. 921: Association between Ejaculatory Dysfunction and Therapy Among Men Enrolled in the BPH Registry & Patient Survey